EGFR and neoplasm: In vitro studies have revealed that tumor cells carrying non-T790 M mutations show a partial resistance to EGFR-TKI, but are much less resistant compared to cells with T790 M. These data suggest that an increased EGFR-TKI dose might circumvent the acquired resistance caused by non-T790 M mutations.